The Director of the Butantan Institute on Tuesday contradicted the words of Uruguayan President Luis Lacalle Pou, assuring that there is not yet a closed agreement between the Uruguayan government and the Chinese laboratory Sinovac for the purchase of the vaccine against Covid-19. However, the institute affirmed that there is a pre-agreement and talks are still ongoing. Lacalle Pou announced on Saturday at a press conference the purchase of 1.75 million doses from this laboratory.
With the slow development of its own phase three clinical trial of a Covid-19 vaccine candidate, Indonesia said it has asked for data from Brazil, where a similar trial is progressing smoothly.
Brazilian researchers said on Wednesday the COVID-19 vaccine developed by China's Sinovac Biotech is more than 50% effective based on trial data, but again withheld full results at the company's request, raising questions about transparency.
Chinese vaccine maker Sinovac Biotech Ltd's Covid-19 vaccine has shown to be effective in late-stage trials in Brazil, the Wall Street Journal reported on Monday, citing people involved in the vaccine's development.
Brazil’s health regulator Anvisa said China’s health authorities are not transparent in their authorization of COVID-19 vaccines for emergency use, a statement that may further inflame political tension in the country.
Brazil’s national health regulator allowed clinical trials of a Chinese-developed Covid-19 vaccine to resume on Wednesday, two days after suspending them in what critics called a decision tainted by politics.